Is TLPH or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Minerva Neurosciences N/A N/A -31.72%

Does the media refer more to TLPH or NERV?

In the previous week, Talphera and Talphera both had 2 articles in the media. Talphera's average media sentiment score of 0.65 beat Minerva Neurosciences' score of 0.62 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, IMUX or TLPH?

Talphera has higher revenue and earnings than Immunic. Talphera is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Talphera $30K 2,076.40 -$14.29M -$0.27 N/A

Is IMUX or TLPH more profitable?

Talphera's return on equity of -87.28% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Talphera N/A -87.28% -51.36%

Does the media prefer IMUX or TLPH?

In the previous week, Immunic had 2 more articles in the media than Talphera. MarketBeat recorded 4 mentions for Immunic and 2 mentions for Talphera. Talphera's average media sentiment score of 0.65 beat Immunic's score of 0.47 indicating that Talphera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Talphera 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DERM or TLPH?

In the previous week, Journey Medical had 1 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for Talphera. Journey Medical's average media sentiment score of 1.52 beat Talphera's score of 0.65 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Talphera 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRDL or TLPH more profitable?

Talphera's return on equity of -87.28% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Talphera N/A -87.28% -51.36%

Does the media refer more to CRDL or TLPH?

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 2 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.96 beat Talphera's score of 0.65 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Talphera (TLPH) Competitors

$1.20 -0.03 (-2.44%)

As of 08/28/2026 04:00 PM Eastern

Compare

TLPH vs. NERV, IMUX, DERM, SLGL, and CRDL

Should you buy Talphera stock or one of its competitors? Talphera's main competitors and comparable companies include Minerva Neurosciences (NERV), Immunic (IMUX), Journey Medical (DERM), Sol-Gel Technologies (SLGL), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Talphera compare to Minerva Neurosciences?

Talphera (NASDAQ:TLPH) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Talphera has higher revenue and earnings than Minerva Neurosciences. Talphera is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

37.7% of Talphera shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Minerva Neurosciences	N/A	N/A	-31.72%

Talphera presently has a consensus target price of $3.00, suggesting a potential upside of 150.00%. Minerva Neurosciences has a consensus target price of $10.33, suggesting a potential upside of 113.50%. Given Talphera's stronger consensus rating and higher probable upside, research analysts clearly believe Talphera is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Talphera and Talphera both had 2 articles in the media. Talphera's average media sentiment score of 0.65 beat Minerva Neurosciences' score of 0.62 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Talphera beats Minerva Neurosciences on 10 of the 13 factors compared between the two stocks.

How does Talphera compare to Immunic?

Immunic (NASDAQ:IMUX) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Talphera's return on equity of -87.28% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Talphera	N/A	-87.28%	-51.36%

In the previous week, Immunic had 2 more articles in the media than Talphera. MarketBeat recorded 4 mentions for Immunic and 2 mentions for Talphera. Talphera's average media sentiment score of 0.65 beat Immunic's score of 0.47 indicating that Talphera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Talphera has higher revenue and earnings than Immunic. Talphera is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A

Immunic currently has a consensus target price of $47.25, indicating a potential upside of 206.82%. Talphera has a consensus target price of $3.00, indicating a potential upside of 150.00%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts clearly believe Immunic is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Immunic beats Talphera on 9 of the 15 factors compared between the two stocks.

How does Talphera compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Journey Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Talphera has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Talphera	N/A	-87.28%	-51.36%

In the previous week, Journey Medical had 1 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for Talphera. Journey Medical's average media sentiment score of 1.52 beat Talphera's score of 0.65 indicating that Journey Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Journey Medical has higher revenue and earnings than Talphera. Journey Medical is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$68.18M	3.09	-$11.43M	-$0.22	N/A
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A

Journey Medical currently has a consensus target price of $14.00, suggesting a potential upside of 87.42%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 150.00%. Given Talphera's higher probable upside, analysts clearly believe Talphera is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Journey Medical beats Talphera on 9 of the 14 factors compared between the two stocks.

How does Talphera compare to Sol-Gel Technologies?

Talphera (NASDAQ:TLPH) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Talphera presently has a consensus target price of $3.00, indicating a potential upside of 150.00%. Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 187.02%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Talphera has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

In the previous week, Talphera had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 2 mentions for Talphera and 1 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.87 beat Talphera's score of 0.65 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Positive
Sol-Gel Technologies	Very Positive

Sol-Gel Technologies has higher revenue and earnings than Talphera. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A
Sol-Gel Technologies	$19.39M	9.97	-$6.13M	-$5.64	N/A

37.7% of Talphera shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Summary

Sol-Gel Technologies beats Talphera on 11 of the 17 factors compared between the two stocks.

How does Talphera compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Cardiol Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 415.46%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 150.00%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A

Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Talphera's return on equity of -87.28% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Talphera	N/A	-87.28%	-51.36%

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 2 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.96 beat Talphera's score of 0.65 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardiol Therapeutics beats Talphera on 7 of the 13 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLPH vs. The Competition

Export

Metric	Talphera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$62.29M	$12.15B	$7.20B	$12.91B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-4.44	787.65	273.16	25.45
Price / Sales	2,076.40	795.08	634.73	93.93
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	4.29	11.97	12.98	6.14
Net Income	-$14.29M	$2.83B	$3.48B	$348.86M
7 Day Performance	0.84%	0.39%	0.13%	-0.80%
1 Month Performance	-11.44%	5.34%	7.08%	4.13%
1 Year Performance	121.81%	6.05%	24.67%	15.17%

Talphera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLPH Talphera	2.7979 of 5 stars	$1.20 -2.4%	$3.00 +150.0%	+121.8%	$62.29M	$30K	N/A	19
NERV Minerva Neurosciences	2.3292 of 5 stars	$5.00 +4.0%	$10.33 +106.7%	+105.1%	$229.67M	N/A	N/A	9
IMUX Immunic	3.1341 of 5 stars	$16.42 -0.2%	$47.25 +187.8%	+87.8%	$224.59M	N/A	N/A	70	Analyst Forecast
DERM Journey Medical	1.8101 of 5 stars	$7.53 -4.8%	$14.00 +85.9%	+3.6%	$223.26M	$61.86M	N/A	90
SLGL Sol-Gel Technologies	3.8532 of 5 stars	$81.72 +5.6%	$197.50 +141.7%	+201.9%	$217.46M	$19.39M	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLPH) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Talphera (TLPH) Competitors

TLPH vs. NERV, IMUX, DERM, SLGL, and CRDL

How does Talphera compare to Minerva Neurosciences?

Summary

How does Talphera compare to Immunic?

Summary

How does Talphera compare to Journey Medical?

Summary

How does Talphera compare to Sol-Gel Technologies?

Summary

How does Talphera compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Talphera (TLPH) Competitors

TLPH vs. NERV, IMUX, DERM, SLGL, and CRDL

How does Talphera compare to Minerva Neurosciences?

Which has better earnings & valuation, TLPH or NERV?

Do insiders & institutionals hold more shares of TLPH or NERV?

Which has more risk and volatility, TLPH or NERV?

Is TLPH or NERV more profitable?

Do analysts recommend TLPH or NERV?

Does the media refer more to TLPH or NERV?

Summary

How does Talphera compare to Immunic?

Do institutionals & insiders believe in IMUX or TLPH?

Is IMUX or TLPH more profitable?

Does the media prefer IMUX or TLPH?

Which has more volatility and risk, IMUX or TLPH?

Which has stronger earnings & valuation, IMUX or TLPH?

Do analysts rate IMUX or TLPH?

Summary

How does Talphera compare to Journey Medical?

Which has more volatility and risk, DERM or TLPH?

Is DERM or TLPH more profitable?

Does the media refer more to DERM or TLPH?

Which has better earnings and valuation, DERM or TLPH?

Do analysts prefer DERM or TLPH?

Do institutionals and insiders have more ownership in DERM or TLPH?

Summary

How does Talphera compare to Sol-Gel Technologies?

Do analysts recommend TLPH or SLGL?

Is TLPH or SLGL more profitable?

Does the media favor TLPH or SLGL?

Which has better valuation & earnings, TLPH or SLGL?

Do institutionals and insiders believe in TLPH or SLGL?

Which has more risk & volatility, TLPH or SLGL?

Summary

How does Talphera compare to Cardiol Therapeutics?

Do analysts recommend CRDL or TLPH?

Which has stronger valuation & earnings, CRDL or TLPH?

Which has more risk and volatility, CRDL or TLPH?

Do institutionals & insiders hold more shares of CRDL or TLPH?

Is CRDL or TLPH more profitable?

Does the media refer more to CRDL or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools